Arbutus Biopharma Quarterly Income Statements Chart
Quarterly
|
Annual
Arbutus Biopharma Quarterly Income Statements Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | 2018-03-31 | 2017-12-31 | 2017-09-30 | 2017-06-30 | 2017-03-31 | 2016-12-31 | 2016-09-30 | 2016-06-30 | 2016-03-31 | 2015-12-31 | 2015-09-30 | 2015-06-30 | 2015-03-31 | 2014-12-31 | 2014-09-30 | 2014-06-30 | 2014-03-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| revenue | 1,098,250 | 3,061,000 | 653,000 | 679,000 | 1,678,000 | 1,587,000 | 1,244,000 | 1,436,000 | 2,041,500 | 6,892,000 | ||||||||||||||||||||||||||||||||||||||||
| yoy | -34.55% | 92.88% | -47.51% | -52.72% | -17.81% | -76.97% | ||||||||||||||||||||||||||||||||||||||||||||
| qoq | -64.12% | 368.76% | -3.83% | -59.54% | 5.73% | 27.57% | -13.37% | -29.66% | -70.38% | |||||||||||||||||||||||||||||||||||||||||
| collaborations and licenses | 10,213,000 | 1,316,000 | 1,058,000 | 767,000 | 1,155,000 | 939,000 | 945,000 | 3,935,000 | 3,885,000 | 5,509,000 | 3,985,000 | 3,607,000 | 12,556,000 | 11,218,000 | 1,061,000 | 1,480,000 | 1,185,000 | 1,154,000 | 1,032,000 | 827,000 | 825,000 | |||||||||||||||||||||||||||||
| non-cash royalty revenue | 526,000 | 448,000 | 516,000 | 572,000 | 571,000 | 593,000 | 1,200,000 | 723,000 | 766,000 | 1,178,000 | 2,260,000 | 2,345,000 | 1,685,000 | 1,363,000 | 2,145,000 | 1,860,000 | 1,144,000 | 959,000 | 1,354,000 | 696,000 | 689,000 | 656,000 | ||||||||||||||||||||||||||||
| total revenue | 10,739,000 | 1,764,000 | 1,574,000 | 1,339,000 | 1,726,000 | 1,532,000 | 2,145,000 | 4,658,000 | 4,651,000 | 6,687,000 | 6,245,000 | 5,952,000 | 14,241,000 | 12,581,000 | 3,206,000 | 3,340,000 | 2,329,000 | 2,113,000 | 2,386,000 | 1,523,000 | 1,514,000 | 1,491,000 | 1,039,000 | 235,000 | -195,000 | 774,000 | 309,000 | 603,000 | 12,686,000 | 4,065,000 | 3,440,000 | 4,682,000 | 4,350,000 | 4,362,000 | 1,811,000 | 4,430,000 | ||||||||||||||
| operating expenses | ||||||||||||||||||||||||||||||||||||||||||||||||||
| research and development | 5,498,000 | 8,959,000 | 8,810,000 | 14,273,000 | 15,551,000 | 15,403,000 | 17,564,000 | 20,169,000 | 17,692,000 | 18,275,000 | 22,949,000 | 20,055,000 | 22,942,000 | 18,462,000 | 20,437,000 | 16,299,000 | 15,396,000 | 13,370,000 | 14,535,000 | 12,065,000 | 10,465,000 | 10,416,000 | 12,418,000 | 17,731,000 | ||||||||||||||||||||||||||
| general and administrative | 3,328,000 | 5,832,000 | 4,712,000 | 4,537,000 | 7,547,000 | 5,312,000 | 5,101,000 | 5,842,000 | 5,980,000 | 5,552,000 | 4,249,000 | 3,493,000 | 5,200,000 | 4,892,000 | 4,698,000 | 4,146,000 | 4,445,000 | 3,847,000 | 3,540,000 | 4,065,000 | 3,566,000 | 3,553,000 | 1,877,000 | 3,249,000 | 8,189,000 | 4,412,000 | 5,927,000 | 2,631,000 | 3,775,000 | 3,669,000 | 3,543,000 | 3,659,000 | 4,599,000 | 4,328,000 | 4,733,000 | 3,720,000 | 23,766,000 | 7,219,000 | 8,354,000 | 7,706,000 | 7,662,000 | 2,716,000 | 3,082,000 | 1,764,000 | 1,787,000 | 2,050,000 | ||||
| change in fair value of contingent consideration | 260,000 | 299,000 | 1,890,000 | 344,000 | 211,000 | 180,000 | 227,000 | 205,000 | -636,000 | 273,000 | 1,609,000 | 215,000 | 208,000 | 201,000 | 193,000 | 856,000 | 694,000 | 129,000 | 125,000 | 120,000 | 116,000 | 112,000 | 30,250 | 376,000 | ||||||||||||||||||||||||||
| restructuring costs | 165,000 | |||||||||||||||||||||||||||||||||||||||||||||||||
| total operating expenses | 9,251,000 | 27,463,000 | 15,507,000 | 22,779,000 | 23,309,000 | 20,895,000 | 22,892,000 | 26,216,000 | 23,036,000 | 24,100,000 | 28,807,000 | 23,763,000 | 28,350,000 | 23,555,000 | 24,002,000 | 21,748,000 | 20,971,000 | 17,789,000 | 18,687,000 | 16,740,000 | 14,655,000 | 14,638,000 | 14,705,000 | 94,462,000 | ||||||||||||||||||||||||||
| gain from operations | 1,488,000 | |||||||||||||||||||||||||||||||||||||||||||||||||
| other income | ||||||||||||||||||||||||||||||||||||||||||||||||||
| interest income | 1,042,000 | 1,197,000 | 1,464,000 | 1,747,000 | 1,829,000 | 1,545,000 | 1,465,000 | 1,494,000 | 1,461,000 | 1,268,000 | 943,000 | 694,000 | 396,000 | 159,000 | 30,000 | 27,000 | 31,000 | 39,000 | 96,000 | 100,000 | 200,000 | 345,000 | 402,000 | 503,000 | 606,000 | 600,000 | 728,000 | 756,000 | 805,000 | 758,000 | 443,000 | 337,000 | 390,000 | 368,000 | 287,000 | 425,000 | 435,000 | 244,000 | 208,000 | 183,000 | 81,000 | 202,000 | 145,000 | 304,000 | 257,000 | 147,000 | ||||
| interest expense | -28,000 | -28,000 | -30,000 | -29,000 | -34,000 | -44,000 | -44,000 | -46,000 | -171,000 | -198,000 | -309,000 | -429,000 | -482,000 | -506,000 | -560,000 | -762,000 | -763,000 | -772,000 | -797,000 | -1,074,000 | -1,099,000 | -1,041,000 | -994,000 | -1,100,000 | -2,000 | -12,000 | -122,000 | |||||||||||||||||||||||
| foreign exchange gain | 21,000 | -13,000 | 4,000 | 3,000 | -15,000 | -13,000 | 28,000 | -40,000 | -19,000 | -47,000 | 10,750 | -25,000 | 60,000 | 8,000 | -185,000 | 145,000 | -359,000 | 614,500 | 1,233,000 | |||||||||||||||||||||||||||||||
| total other income | 1,035,000 | 1,173,000 | 1,401,000 | 1,723,000 | 1,787,000 | 1,488,000 | 1,435,000 | 1,454,000 | 1,291,000 | 1,074,000 | 630,000 | 244,000 | -11,567,000 | -3,758,000 | -2,800,000 | -4,180,000 | -1,346,000 | 3,671,000 | 25,137,000 | 976,000 | -2,000 | 1,297,000 | 1,230,000 | -1,394,000 | 384,000 | 4,103,000 | 5,505,000 | 13,960,000 | ||||||||||||||||||||||
| net income | 2,523,000 | -24,526,000 | -12,532,000 | -19,717,000 | -19,796,000 | -17,875,000 | -19,312,000 | -20,104,000 | -17,094,000 | -16,339,000 | -21,932,000 | -17,567,000 | -14,192,000 | -15,765,000 | -21,321,000 | -19,158,000 | -19,387,000 | -16,381,000 | -17,042,000 | -18,755,000 | -14,087,000 | -13,861,000 | -24,654,000 | -82,503,000 | -23,251,000 | 3,091,000 | -17,429,000 | -18,627,000 | -218,695,000 | -19,595,000 | -130,000,000 | -15,874,000 | -14,886,000 | -11,989,000 | -6,168,000 | -8,604,000 | -6,081,000 | -17,984,000 | ||||||||||||
| yoy | -112.74% | 37.21% | -35.11% | -1.92% | 15.81% | 9.40% | -11.95% | 14.44% | 20.45% | 3.64% | 2.87% | -8.30% | -26.80% | -3.76% | 25.11% | 2.15% | 37.62% | 18.18% | -30.88% | -77.27% | -40.39% | 33.40% | -6.43% | 17.34% | 773.30% | 32.40% | 144.80% | -33.34% | ||||||||||||||||||||||
| qoq | -110.29% | 95.71% | -36.44% | -0.40% | 10.75% | -7.44% | -3.94% | 17.61% | 4.62% | -25.50% | 24.85% | 23.78% | -9.98% | -26.06% | 11.29% | -1.18% | 18.35% | -3.88% | -9.13% | 33.14% | 1.63% | -43.78% | -70.12% | -117.73% | -91.48% | 1016.08% | -84.93% | 718.95% | 24.16% | 94.37% | -28.31% | 41.49% | -66.19% | |||||||||||||||||
| net income margin % | -2244.84% | -2695.30% | 0% | -3424.30% | 0% | 0% | 248.47% | -1213.72% | 0% | 0% | ||||||||||||||||||||||||||||||||||||||||
| net income per common share | ||||||||||||||||||||||||||||||||||||||||||||||||||
| basic | 10 | |||||||||||||||||||||||||||||||||||||||||||||||||
| diluted | 10 | |||||||||||||||||||||||||||||||||||||||||||||||||
| weighted-average number of common shares | ||||||||||||||||||||||||||||||||||||||||||||||||||
| basic | 191,551,282,000 | 56,805,583 | 55,304,083 | 55,211,294 | 54,723,272 | 53,074,401,000 | 45,462,324,000 | 21,603,136,000 | ||||||||||||||||||||||||||||||||||||||||||
| diluted | 192,399,733,000 | 56,805,583 | 55,304,083 | 56,487,220 | 54,723,272 | 53,074,401,000 | 45,462,324,000 | 21,603,136,000 | ||||||||||||||||||||||||||||||||||||||||||
| comprehensive income | 2,502,000 | |||||||||||||||||||||||||||||||||||||||||||||||||
| unrealized gain on available-for-sale securities | -21,000 | -31 | -45 | 218 | 63 | 50 | 401 | 584 | 166 | 854 | -691 | -1,071 | -148 | -31 | -31 | 3 | -44 | -72 | 122 | 251,000 | ||||||||||||||||||||||||||||||
| restructuring | 12,373,000 | 906,250 | 3,625,000 | |||||||||||||||||||||||||||||||||||||||||||||||
| income from operations | -25,699,000 | -13,933,000 | -21,440,000 | -21,583,000 | -19,363,000 | -20,747,000 | -21,558,000 | -18,385,000 | -17,413,000 | -22,562,000 | -17,811,000 | -14,109,000 | -10,974,000 | -20,796,000 | -18,408,000 | -18,642,000 | -15,676,000 | -16,301,000 | -15,217,000 | -13,141,000 | -13,147,000 | -13,087,000 | -91,401,000 | -20,515,000 | -19,071,000 | -16,903,000 | -32,426,000 | -22,046,000 | -14,420,000 | -18,006,000 | -10,747,000 | -6,844,000 | -9,423,000 | -5,958,000 | ||||||||||||||||
| yoy | 32.72% | -32.84% | -0.55% | 17.39% | 11.20% | -8.04% | 21.04% | 30.31% | 58.68% | 8.49% | -3.24% | -24.32% | -29.99% | 27.57% | 20.97% | 41.86% | 19.24% | 24.56% | -83.35% | -35.94% | -31.06% | -22.58% | 181.88% | -6.94% | 53.03% | 202.22% | ||||||||||||||||||||||||
| qoq | 84.45% | -35.01% | -0.66% | 11.47% | -6.67% | -3.76% | 17.26% | 5.58% | -22.82% | 26.67% | 26.24% | 28.57% | -47.23% | 12.97% | -1.26% | 18.92% | -3.83% | 7.12% | 15.80% | -0.05% | 0.46% | -85.68% | 345.53% | 7.57% | 12.83% | -47.87% | 47.08% | -19.92% | 67.54% | 57.03% | -27.37% | 58.16% | ||||||||||||||||||
| operating margin % | -1191.62% | -2985.98% | -3141.65% | -2808.69% | -1007.33% | -2043.23% | -1772.19% | 0% | ||||||||||||||||||||||||||||||||||||||||||
| foreign exchange gain/ | 4,000 | -4,000 | 5,000 | |||||||||||||||||||||||||||||||||||||||||||||||
| loss per share | ||||||||||||||||||||||||||||||||||||||||||||||||||
| basic and diluted | -0.13 | -0.07 | -0.1 | -0.11 | -0.1 | -0.12 | -0.12 | -0.1 | -0.1 | -0.14 | -0.12 | -0.1 | -0.11 | -0.15 | -0.24 | -0.23 | -0.21 | -0.23 | -0.27 | -0.25 | ||||||||||||||||||||||||||||||
| weighted-average number of common shares | ||||||||||||||||||||||||||||||||||||||||||||||||||
| basic and diluted | 190,707,085 | 185,608,874 | 188,997,194 | 188,041,489 | 175,625,552 | 165,960,379 | 167,512,708 | 166,063,284 | 161,643,404 | 150,939,337 | 150,995,191 | 148,750,048 | 148,428,326 | 106,242,452 | 101,286,351 | 96,869,805 | 93,434,378 | 75,835,378 | 79,487,444 | 69,604,726 | 67,683,586,000 | 57,093,454,000 | 56,850,172 | 55,740,121 | 55,421,504,000 | 55,071,964 | 54,877,103,000 | 54,647,944,000 | 54,307,464,000 | 53,652,007,000 | 52,716,059,000 | 51,400,485,000 | 50,756,484,000 | 54,255,804,000 | 30,208,136,000 | 22,159,269,000 | 22,063,438,000 | 19,801,428,000 | ||||||||||||
| comprehensive loss | -24,557 | -12,577 | -19,499 | -19,733 | -17,825 | -18,849 | -19,520 | -16,928 | -15,485 | -21,416 | -18,474 | -14,883 | -16,836 | -21,469 | -19,189 | -19,418 | -16,378 | -17,086 | -18,783 | -13,965 | -13,610,000 | -218,695,000 | -19,595,000 | -130,000,000 | -15,874,000 | -11,663,000 | -21,163,000 | -9,446,000 | -13,431,000 | -2,307,000 | -20,143,000 | |||||||||||||||||||
| foreign exchange (loss)/gain | -8,000 | |||||||||||||||||||||||||||||||||||||||||||||||||
| foreign exchange (gain) loss | 2,750 | 6,000 | 1,000 | |||||||||||||||||||||||||||||||||||||||||||||||
| income before income taxes | -19,312,000 | -20,104,000 | -17,094,000 | -16,339,000 | -21,932,000 | -17,567,000 | -14,192,000 | -11,321,000 | -13,731,500 | -19,158,000 | -19,387,000 | -16,381,000 | -17,042,000 | -18,755,000 | -14,087,000 | -13,861,000 | -24,654,000 | -95,159,000 | ||||||||||||||||||||||||||||||||
| income tax expense | -4,444,000 | |||||||||||||||||||||||||||||||||||||||||||||||||
| foreign exchange loss | -4,500 | -21,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
| items applicable to preferred shares: | ||||||||||||||||||||||||||||||||||||||||||||||||||
| dividend accretion of convertible preferred shares | -574,000 | -5,087,000 | -3,266,000 | -3,212,000 | -3,123,000 | -3,027,000 | -2,995,000 | -2,978,000 | ||||||||||||||||||||||||||||||||||||||||||
| net income attributable to common shares | -21,932,000 | -17,567,000 | -14,192,000 | -15,765,000 | -21,895,000 | -24,245,000 | -22,653,000 | -19,593,000 | -20,165,000 | -21,782,000 | -17,082,000 | -16,839,000 | -26,077,000 | -25,966,000 | 550,000 | -19,765,000 | ||||||||||||||||||||||||||||||||||
| unrealized loss on available-for-sale securities | 516 | -907 | ||||||||||||||||||||||||||||||||||||||||||||||||
| total other loss | -83,000 | -347,000 | -525,000 | -750,000 | -745,000 | -705,000 | -741,000 | -3,538,000 | -946,000 | -714,000 | ||||||||||||||||||||||||||||||||||||||||
| dividend accretion of convertible preferred shares. | ||||||||||||||||||||||||||||||||||||||||||||||||||
| depreciation | 331,500 | 447,000 | 436,000 | 443,000 | 500,000 | 507,000 | 507,000 | 505,000 | 509,000 | |||||||||||||||||||||||||||||||||||||||||
| site consolidation | 7,000 | 57,000 | 123,000 | 182,000 | -266,000 | 117,000 | 1,087,000 | -492,000 | 2,581,000 | 1,621,000 | ||||||||||||||||||||||||||||||||||||||||
| equity investment loss | -2,545,000 | -2,874,250 | -3,512,000 | -3,334,000 | -709,500 | -2,838,000 | ||||||||||||||||||||||||||||||||||||||||||||
| currency translation adjustments | 44 | |||||||||||||||||||||||||||||||||||||||||||||||||
| depreciation and amortization | 372,750 | 490,000 | 501,000 | |||||||||||||||||||||||||||||||||||||||||||||||
| impairment of intangible assets | 43,836,000 | 14,811,000 | 96,873,000 | 156,324,000 | 1,017,000 | 37,990,000 | ||||||||||||||||||||||||||||||||||||||||||||
| impairment of goodwill | 22,471,000 | |||||||||||||||||||||||||||||||||||||||||||||||||
| arbitration | -220,000 | 6,486,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
| income tax benefit | 12,656,000 | 1,070,500 | 4,282,000 | 16,216,000 | 64,864,000 | 3,799,000 | 15,196,000 | |||||||||||||||||||||||||||||||||||||||||||
| currency translation adjustment | ||||||||||||||||||||||||||||||||||||||||||||||||||
| revenue from collaborations and licenses | 835,000 | |||||||||||||||||||||||||||||||||||||||||||||||||
| foreign exchange (losses) / gains | -18,000 | |||||||||||||||||||||||||||||||||||||||||||||||||
| net equity investment loss | ||||||||||||||||||||||||||||||||||||||||||||||||||
| net income per common share | ||||||||||||||||||||||||||||||||||||||||||||||||||
| basic and diluted | -250 | |||||||||||||||||||||||||||||||||||||||||||||||||
| gain on investment | 24,884,000 | |||||||||||||||||||||||||||||||||||||||||||||||||
| accrual of coupon on convertible preferred shares | -2,067,250 | -2,792,000 | -2,762,000 | -2,715,000 | -2,647,000 | -2,567,000 | -2,541,000 | |||||||||||||||||||||||||||||||||||||||||||
| net income attributable to common shareholders | -34,334,500 | -85,295,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
| net income attributable to common shareholders, per share | ||||||||||||||||||||||||||||||||||||||||||||||||||
| basic and diluted | -0.608 | -1.5 | -0.47 | -0.36 | ||||||||||||||||||||||||||||||||||||||||||||||
| expenses | ||||||||||||||||||||||||||||||||||||||||||||||||||
| research, development, collaborations and contracts | 12,740,000 | 14,712,000 | 11,717,750 | 16,566,000 | 16,356,000 | 13,949,000 | 17,822,000 | 15,537,000 | 15,445,000 | 13,872,000 | 17,156,000 | 15,738,000 | 15,215,000 | 13,144,000 | 14,904,000 | 16,354,000 | 9,690,000 | 10,557,000 | 9,298,000 | 8,204,000 | ||||||||||||||||||||||||||||||
| total expenses | 21,168,000 | 19,750,000 | 18,581,000 | 34,013,000 | 23,290,000 | 19,841,000 | 62,783,000 | 19,789,000 | 20,524,000 | 18,534,000 | 257,244,000 | 19,749,000 | 195,557,000 | 20,580,000 | 24,444,000 | 62,203,000 | 17,860,000 | 22,688,000 | 15,097,000 | 11,206,000 | 11,234,000 | 10,388,000 | ||||||||||||||||||||||||||||
| decrease | -130,000 | -125,000 | 1,565,750 | 5,608,000 | -193,000 | 161,000 | 564,000 | 1,976,000 | ||||||||||||||||||||||||||||||||||||||||||
| net income before income taxes | -23,315,000 | |||||||||||||||||||||||||||||||||||||||||||||||||
| net income attributable to common shareholders, per share | ||||||||||||||||||||||||||||||||||||||||||||||||||
| basic | -0.46 | 0.01 | ||||||||||||||||||||||||||||||||||||||||||||||||
| diluted | -0.46 | 0.01 | ||||||||||||||||||||||||||||||||||||||||||||||||
| equity investment | -4,651,000 | |||||||||||||||||||||||||||||||||||||||||||||||||
| depreciation of property and equipment | 504,000 | 497,000 | 578,000 | 602,000 | 620,000 | 593,000 | 480,000 | 334,000 | 332,000 | 291,000 | 252,000 | 217,000 | 169,000 | 153,000 | 147,000 | 120,000 | 113,000 | 133,000 | 149,000 | 134,000 | ||||||||||||||||||||||||||||||
| increase in fair value of warrant liability | -1,223,000 | 2,560,000 | -5,140,000 | 5,813,000 | -13,616,000 | |||||||||||||||||||||||||||||||||||||||||||||
| net (loss) before income taxes | -10,773,250 | -28,755,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
| net | -9,702,750 | -24,473,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
| net (loss) attributable to common shares | -11,563,750 | -27,040,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
| basic and diluted | -210 | -490 | ||||||||||||||||||||||||||||||||||||||||||||||||
| decrease (increase) in fair value of warrant liability | ||||||||||||||||||||||||||||||||||||||||||||||||||
| items applicable to preferred shares | ||||||||||||||||||||||||||||||||||||||||||||||||||
| gain on disposition of financial instrument | 1,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||
| increase in fair value of contingent consideration | ||||||||||||||||||||||||||||||||||||||||||||||||||
| net and comprehensive loss | -12,120,500 | -11,600,000 | -18,255,000 | |||||||||||||||||||||||||||||||||||||||||||||||
| loss per common share | ||||||||||||||||||||||||||||||||||||||||||||||||||
| basic and diluted | -222.5 | -210 | -330 | -340 | -787.5 | -370 | -2,470 | -310 | -270 | -400 | -382.5 | -390 | -280 | |||||||||||||||||||||||||||||||||||||
| collaborations and contracts | 318,000 | 18,000 | 3,000 | 87,000 | 32,000 | 107,000 | 4,444,000 | 3,035,000 | 2,310,000 | 3,520,000 | 3,327,000 | 3,578,000 | 1,144,000 | 3,689,000 | ||||||||||||||||||||||||||||||||||||
| licensing fees, milestone and royalty payments | 721,000 | 217,000 | -198,000 | 687,000 | 277,000 | 496,000 | 8,242,000 | 1,030,000 | 1,130,000 | 1,162,000 | 667,000 | 741,000 | ||||||||||||||||||||||||||||||||||||||
| foreign exchange gains | 798,000 | 427,000 | -1,060,000 | 33,000 | 2,942,000 | 5,503,000 | 11,801,000 | -2,571,000 | 7,038,000 | 2,336,000 | 3,076,000 | 1,443,000 | ||||||||||||||||||||||||||||||||||||||
| decrease in fair value of warrant liability | 84,750 | 10,000 | 168,000 | |||||||||||||||||||||||||||||||||||||||||||||||
| acquisition costs | 361,000 | 9,295,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
| cumulative translation adjustment | 3,223,000 | -9,174,000 | -3,278,000 | -4,827,000 | 3,774,000 | -2,159,000 | ||||||||||||||||||||||||||||||||||||||||||||
| licensing fees, milestone and | ||||||||||||||||||||||||||||||||||||||||||||||||||
| royalty payments | 548,000 | 784,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
| research, development, collaborations | ||||||||||||||||||||||||||||||||||||||||||||||||||
| and contracts | 6,702,750 | 9,309,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
| foreign exchange losses | -2,728,000 | |||||||||||||||||||||||||||||||||||||||||||||||||
| income per common share | ||||||||||||||||||||||||||||||||||||||||||||||||||
| basic and diluted | -910 |
We provide you with 20 years income statements for Arbutus Biopharma stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Arbutus Biopharma stock. Explore the full financial landscape of Arbutus Biopharma stock with our expertly curated income statements.
The information provided in this report about Arbutus Biopharma stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.